BEAM · Beam Therapeutics Inc.

BEAM reports earnings on Nov 3, 2026 — a breakout right before a report can reverse on the numbers.

Not today. BEAM is not on today's radar: no tight base just under a resistance that has been tested again and again.

Bulls: Beam Therapeutics reported initial Phase 1/2 clinical data for BEAM-301, a liver-targeting LNP formulation of adenine base editors designed to correct the R83C mutation as a "one and done" therapy for GSDIa, demonstrating proof of concept for genetic correction; in the 40 mg dose cohort, 2 of 3 patients completed a controlled 15-hour fast and stopped relying on starch, with dose-dependent improvements in time to fasting hypoglycemia (TTH) and restored glucose production after a single administration. H.C. Wainwright reiterated its Buy rating and $80 price target, saying the ESGCT-presented data strengthens conviction in the platform across hematology and liver-targeted genetic diseases and raises probability of success for both BEAM-302 and BEAM-301, with the stock cited as seeing further ~200% upside. The stock was noted up ~40% from its breakout zone and +16.8% in 24h / +57.2% over 30d, and one post argued the new FDA draft guidance for Individualized Human Genome Editing Products was essentially written for $BEAM and $PRME.

Bears: One chart read flagged a clear bearish structure with price trending downward below major moving averages and sellers in control. Another warned that follow-through, not the first pump, is what needs to hold — sustained volume or an actual catalyst — otherwise it fades back, calling a retest of the lows by Friday if volume doesn't follow through.

Reading from Oct 28, 2026; each post classified by AI, weighted by engagement.

No recent news reading for BEAM. The News Sentiment API reads today's headlines on any US stock.

Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.

• Sold · Evans John M.$600K · Oct 16, 2026
• Sold · Evans John M.$589K · Oct 15, 2026
• Sold · Simon Amy$429K · Jul 27, 2026
• Sold · Evans John M.$66K · Jun 30, 2026
• Sold · Evans John M.$791K · Jun 30, 2026

From the company's SEC filings (10-Q and 10-K).

• full year 2026 · cash runway · 8-K filed Aug 4, 2026

  “Beam expects that its cash, cash equivalents and marketable securities as of June 30, 2026, together with an additional $200 million expected to be drawn from the company’s facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029, funding the company through the anticipated launch of risto-cel in SCD, execution of the BEAM-302 pivotal development plan in AATD, and clinical proof of concept for BEAM-304 in PKU.”

• 2026 · beam-302 pivotal cohort initiation · 8-K filed May 7, 2026

  “Beam expects to initiate this pivotal cohort in the second half of 2026.”

• 2026 · beam-304 ind application filing · 8-K filed May 7, 2026

  “Beam expects to file an investigational new drug (IND) application with the FDA for BEAM-304 in 2026 following completion of pre-IND activities.”

• 2026 · beam-301 initial clinical data · 8-K filed May 7, 2026

  “Beam expects to report initial clinical data in 2026.”

Quoted from the outlook the company filed with the SEC.